## Ahmed A Moustafa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5005516/publications.pdf

Version: 2024-02-01

1307366 1588896 12 274 7 8 citations g-index h-index papers 12 12 12 619 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Combination of Tipifarnib and Sunitinib Overcomes Renal Cell Carcinoma Resistance to Tyrosine Kinase Inhibitors via Tumor-Derived Exosome and T Cell Modulation. Cancers, 2022, 14, 903.	1.7	15
2	A dual drug therapy for sunitinib resistant RCC: An in vitro analysis Journal of Clinical Oncology, 2021, 39, 340-340.	0.8	1
3	Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma. Scientific Reports, 2021, 11, 10200.	1.6	23
4	Interleukin-17 Promotes Migration and Invasion of Human Cancer Cells Through Upregulation of MTA1 Expression. Frontiers in Oncology, 2019, 9, 546.	1.3	30
5	Th17 cells promote tumor growth in an immunocompetent orthotopic mouse model of prostate cancer. American Journal of Clinical and Experimental Urology, 2019, 7, 249-261.	0.4	5
6	MicroRNAs in prostate cancer: From function to biomarker discovery. Experimental Biology and Medicine, 2018, 243, 817-825.	1.1	18
7	Identification of microRNA signature and potential pathway targets in prostate cancer. Experimental Biology and Medicine, 2017, 242, 536-546.	1.1	15
8	Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells. Cancer Letters, 2017, 408, 73-81.	3.2	158
9	Pioglitazone Enhances Survival and Regeneration of Pelvic Ganglion Neurons After Cavernosal Nerve Injury. Urology, 2016, 89, 76-82.	0.5	9
10	Abstract 424: Urine cf-DNA SNPs as early biomarkers of prostate cancer. , 2016, , .		0
11	Abstract 1775: Differential expression of exosomes-associated onco-microRNAs in African Americans with prostate cancer. , $2016, \ldots$		O
12	Abstract 1882: Manumycin-A suppresses exosome biogenesis and chemosensitizes CRPC cells to enzalutamide through inhibition of Ras/Raf/ERK1/2 signaling pathway. , 2016, , .		0